You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  4. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. A2a Adenosine Blockers for Parkinson's Disease

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity of KW6002. Other investigational compounds lack sufficient potency, selectivity or bioavailability to ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. A2a AR Agonists for Rheumatoid Arthritis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotechnology company, Adenosine Therapeutics, LLC (ATL) based in Charlottesville, VA, and the University of Virginia laboratory of Dr. Donald L. Kimpel, a Rheumatologist experienced in the study of RA. Hum ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Safety of A2A Adenosine Agonist for Treatment of Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands

    SBC: OCATA THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ability to culture human embryonic stem cells generated a great deal of excitement about their vast potential for treating a variety of human diseases such as diabetes, heart disease, neurological, retinal and skin disorders to name a few. Unlike adult stem cells, embryonic stem cells have indefinite growth potential and the potential to develop into any t ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Genetic Assay for Inhibitors of RNA-Protein Interactions

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: N/A

    RNA-protein interactions play critical roles in cellular regulatory processes and in the life cycles of many pathogenic viruses including HIV, hepatitis C, SARS, and West Nile virus, and thus represent attractive targets for therapeutics. We have developed novel cell-based assays to identify drugs that target the RNA-protein interactions. The assays incorporate a system of genetic reporters to acc ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government